The 30th annual JP Morgan Healthcare Conference was held in San Francisco, CA from January 9-12, 2012. A list of events and catalysts that were announced or updated at the conference is included in this report. This report is a combination of the daily updates we sent.

Key events included in JP Morgan coverage:

• Amylin had a successful end of Phase II meeting with the FDA discussing the exenatide suspension program. The weekly Phase III program is planned to commence in mid-2012 and the monthly Phase III program is planned for 2013.
• Teva stated that Omapro for third-line CML is currently under review with the FDA.
• Dendreon announced that it has filed an MAA for Provenge in patients with prostate cancer.
• Shire announced that the company completed the BLA submission in the US for Fabry's disease. The FDA granted Shire a priority review.
• VIVUS announced that following recent discussions with FDA officials, the company has been asked to remove the Qnexa contraindication for women of childbearing potential contained in the proposed label.
• NPS presented additional results from its Phase II STEPS 2 extension study of Gattex (teduglutide) in patients with short bowel syndrome (SBS) who are dependent on parenteral nutrition (PV) or IV fluids.
• Seattle Genetics announced a planned Phase III study of Adcetris as front-line treatment in T-cell lymphoma.
• Nektar announced more details for the Phase II trial of NKTR-181 for chronic pain.
• Celgene announced that it has received fast track designation from the Food and Drug Administration (FDA) for pomalidomide in relapsed/refractory multiple myeloma (RRMM).
• ARIAD provided additional results from the Phase II PACE trial of ponatinib.

Key catalysts included in JP Morgan coverage:

• BioMarin stated that results from the pivotal Phase III study of GALNS are expected in the fourth quarter of 2012.
• Arena and Eisai announced that the PDUFA for the second review of Lorqess has a target date of June 27, 2012.
• Targacept reported that results from the two pivotal Phase III fixed dose studies of TC-5214 and the long-term safety study will be reported in the first half of 2012.
• Pfizer expects data from the Phase III pivotal trials of bapineuzumab in mid-2012.
• Orexigen expects to enroll the first patient from the cardiovascular outcomes trial for Contrave late in the second quarter of 2012.
• Baxter announced that a DSMB will be conducting a futility analysis on the first Phase III study of Gammagard in Alzheimer's Disease patients in the first quarter of 2012.
• Seattle Genetics expects to report interim data from the Phase I front-line study of Adcetris in T-cell lymphoma at the T-Cell Lymphoma Forum held January 26-28, 2012.
• A clinical update on Alpharadin is expected at the ASCO GU conference, which takes place February 2-4, 2012.
• NPS announced that an FDA Advisory Committee meeting to discuss the NDA for Gattex is expected for 2012.
• Celgene expects to file for approval of pomalidomide in RRMM before the end of the first quarter of 2012.

For the list of catalysts in Excel, please contact your sales representative at clientservices@pharmaintel.informa.com.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.